Tag: Asterias Biotherapeutics
September 12, 2018
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular... July 12, 2018
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California
Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular... March 16, 2018
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination... March 1, 2018
Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular... February 15, 2018
Asterias Expands Global IP Portfolio with New Patents
Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat neurological conditions associated with de-myelination and... August 30, 2017
Asterias Shares Publication on Data for AST-OPC1
Asterias Biotherapeutics announced the publication of a peer-reviewed journal describing the efficacy and safety data from a preclinical study on... August 23, 2017